COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
Mult Scler
; 26(10): 1264-1266, 2020 09.
Article
in En
| MEDLINE
| ID: mdl-32762488
ABSTRACT
BACKGROUND:
Most cases of COVID-19 are considered mild, but patients with immunosuppressant treatment might be prone to severe courses of disease. Expert panels advise to delay treatment with cell-depleting MS therapies during the COVID-19 pandemic.METHODS:
We report a case of a patient with relapsing-remitting multiple sclerosis who developed COVID-19 pneumonia 2 weeks after the first week of cladribine therapy.RESULTS:
Despite a severe lymphopenia (absolute lymphocyte count 240/µL), the patient had a moderate course of COVID-19.CONCLUSION:
Apart from maximal supportive treatment, this could be due to cladribine reducing inflammatory response, which probably contributes considerably to severe courses of COVID-19 pneumonia.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Cladribine
/
Coronavirus Infections
/
Multiple Sclerosis, Relapsing-Remitting
/
Immunosuppressive Agents
/
Lymphopenia
Type of study:
Prognostic_studies
Limits:
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Mult Scler
Journal subject:
NEUROLOGIA
Year:
2020
Type:
Article
Affiliation country:
Germany